UK's Tristel half-year revenue up 14%, driven by US growth

Tristel

02/03/2026 07:14

Overview

UK infection prevention product maker's half-year revenue up 14%, driven by US growth

Adjusted EBITDA for half-year rises 17%, maintaining strong margin

Company remains debt-free with strong cash position

Outlook

Tristel aims to scale presence in high-potential markets, focusing on US growth

Company sees US market adoption as a key growth driver

Tristel invests in innovation and market development for long-term value

Result Drivers

US MARKET GROWTH - Tristel's US revenues surged by 542%, driven by product launches and favorable clinical guidelines

PRODUCT LAUNCHES - Launch of Tristel OPH and VISICLEAN™ contributed to revenue growth

IN-HOUSE PRODUCTION - Transition to in-house wipes production impacted costs but expected to benefit margins

Company press release: ID:nRSB7998Ua

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 25.65 mln
H1 Net Income
GBP 3.95 mln
H1 EBIT
GBP 4.89 mln
H1 Gross Profit
GBP 20.78 mln
H1 Pretax Profit
GBP 4.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Tristel PLC is GBp466.00, about 16.5% above its February 27 closing price of GBp400.00

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)